Institutional shares held 124 Million
320K calls
113K puts
Total value of holdings $7.02B
$18.1M calls
$6.4M puts
Market Cap $7.88B
139,288,992 Shares Out.
Institutional ownership 89.04%
# of Institutions 594


Latest Institutional Activity in HALO

Top Purchases

Q2 2025
Livforsakringsbolaget Skandia, Omsesidigt Shares Held: 102K ($5.77M)
Q2 2025
Shelton Wealth Management, LLC Shares Held: 16.2K ($916K)
Q2 2025
Financiere Des Professionnels Fonds D,Investissement Inc. Shares Held: 10.1K ($573K)
Q2 2025
Morris Retirement Advisors, LLC Shares Held: 8.72K ($493K)
Q2 2025
Redhawk Wealth Advisors, Inc. Shares Held: 37.4K ($2.12M)

Top Sells

Q2 2025
Swedbank Ab Shares Held: 157K ($8.89M)
Q2 2025
North Crest Asset Manangement, LLC Shares Held: 21.9K ($1.24M)
Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 14.2K ($802K)
Q2 2025
Juncture Wealth Strategies, LLC Shares Held: 10.5K ($596K)
Q2 2025
Park Avenue Securities LLC Shares Held: 12K ($677K)

About HALO

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.


Insider Transactions at HALO

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
608K Shares
From 10 Insiders
Grant, award, or other acquisition 25K shares
Exercise of conversion of derivative security 583K shares
Sell / Disposition
550K Shares
From 11 Insiders
Open market or private sale 392K shares
Payment of exercise price or tax liability 138K shares
Bona fide gift 20.5K shares

Track Institutional and Insider Activities on HALO

Follow HALOZYME THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO